| Biologic Therapy |
1 |
1 |
| Child |
0 |
0.81 |
| Disease-Modifying Antirheumatic Drugs |
0 |
0.41 |
| Hospital |
0 |
0.41 |
| Arthritis |
0 |
0.3 |
| Revenue and Practice Management |
0 |
0.29 |
| Pain Management |
0 |
0.27 |
| Dorsum |
0 |
0.2 |
| Insurance |
0 |
0.2 |
| Opportunistic Infection |
0 |
0.2 |
| Shared Decision-Making |
0 |
0.17 |
| Patient Safety |
0 |
0.14 |
| Juvenile Rheumatoid Arthritis (JRA) |
0 |
0.99 |
| Adverse Effects |
0 |
0.1 |
| Clinician Health and Well-Being |
0 |
0.1 |
| Cytokines |
0 |
0.1 |
| Exercise |
0 |
0.1 |
| Glucocorticoid |
0 |
0.1 |
| Grant |
0 |
0.1 |
| Interference |
0 |
0.1 |
| Mobility |
0 |
0.1 |
| Pain |
0 |
0.1 |
| Salary and Compensation |
0 |
0.1 |
| Steroids |
0 |
0.1 |
| Medical Life |
0 |
0.05 |